PEPTIDES & PROTEINS
utilises Arrayjet’s proprietary non-contact inkjet technology for fast and precise reproducible microarrays. Dr Holger Wenschuh, the CEO of JPT, comments: “We are very excited about the growing appreciation of our PepStar™ peptide microarray platform by the vaccine and immunotherapy community as well as the diagnostic arena. To comply with large immune monitoring and biomarker discovery projects, thousands of high-content peptide microarrays need to be assembled in our clean-room facilities with the highest reproducibility and accuracy. We are glad to have found a dedicated partner that accepted the specific challenges of our regulated production environment and developed an instrument tailored to our needs.” JPT Peptide Technologies GmbH is a development partner and innovative service provider for peptide-related projects. The company’s key technologies include SPOT™ for ultra-high-throughput peptide synthesis and screening, PepStar™ for high-content peptide microarrays, PepTrack™ for flexible peptide library assembly, PepMix™ for antigen-specific T-cell stimulation using peptide pools, and SpikeTide™ for protein biomarker quantification. These technologies are designed to accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimisation, enzyme profiling and proteomics.
Arrayjet is a specialist in inkjet microarray technology to provide innovative solutions to researchers, drug development groups and diagnostic companies on a global basis through its Arrayjet Advance™ microarray services as well as a range of four scalable inkjet microarray instruments.
Anti-cancer therapies collaboration In a separate development, JPT Peptide Technologies GmbH (JPT) and Spanish companies IUCT and LEITAT have agreed a collaboration on the joint development of an enhanced anti-cancer therapy based on the biofocused targeting of nucleoside analogues linked to small cyclic peptidomimetics. The aim of the partnership is to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds towards tumour cells. The collaboration combines JPT’s expertise in peptide-based hit identification and hit-to-lead
36 sp2 Inter-Active March/April 2012
projects with IUCT’s and LEITAT’s experience in biotechnological synthesis of nucleoside analogues and activity screening studies. The collaborative project is funded in part by the EuroTransbio Initiative.
Established in 1997, IUCT is a high-tech SME working on the development of new products and processes for the pharmaceutical, chemical and biotechnology sectors. As its core business, IUCT performs research in the fields of drug discovery, drug development, industrial biotechnology and green chemistry. In drug discovery, the company’s medicinal chemistry department has extensive experience in indications related to cancer, viral diseases, CNS diseases, inflammation, pain and osteoarthritis. In addition, its Industrial Biotechnology section developed the HTB Platform which allows the synthesis of large numbers of complex molecules not readily accessible by chemical synthesis methods. LEITAT Technological Center is a private research centre that aims to provide process solutions to industry, with a particular focus on the biomedical, oncology, biotechnology and nanotechnology and biomaterials sectors, among others. In the anti-cancer area, LEITAT’s therapeutic research includes the identification of new oncology targets, the generation of novel molecular entities to modulate them, and the characterisation of in vitro and in vivo activity profiles in order to deliver these innovative drugs as clinical development candidates. The centre has recently patented two new NBEs and a disruptive DNA technology with therapeutic and diagnostic applications.
Oramed Pharmaceuticals granted Australian Patent
Oramed Pharmaceuticals has been granted a new Australian Patent that covers part of the company’s core technology allowing for the oral delivery of peptides. Oramed’s portfolio now consists of one issued patent and 34 patents pending for its technologies and products.
The company’s core product is an oral insulin capsule. An oral delivery system for insulin may increase patient value, leading to a healthier lifestyle, especially at the earliest of stages of diabetes treatment. Higher patient compliance may result in improved patient outcomes and a reduction in the costs of health care and lost productivity. According to a report by Medtech Insight, diabetes almost 24 million people in the USA alone and an estimated 246 million adults worldwide. Being one of the most expensive diseases to treat, it costs the US health care system more than $130 billion per year and
the US market for direct pharmaceutical care is almost $15 billion.
“Our patent position further strengthens Oramed and our competitive advantage in the development of an oral insulin capsule. The patent received will provide additional commercial protection for Oramed’s technology and adds extended value to our existing IP-portfolio,” said Nadav Kidron, CEO of Oramed.
Established in 2006, Oramed’s technology is based on over 25 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. The Company’s corporate and R&D headquarters are based in Jerusalem. Oramed Pharmaceuticals is a leading technology developer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company is seeking to change the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Amino acid analysis and N-terminal protein sequencing certification
Alta Bioscience Ltd has had its accreditation to ISO 17025 for amino acid analysis and N- terminal protein sequencing renewed. The company offers these services to academic and commercial customers across a wide range of industries including the pharmaceutical, veterinary, cosmetics and food and drink sectors. In addition, AltaBioscience is now offering lycopene content analysis. This amino acid analysis service now offers lycopene quantification based on methodology developed to determine lycopene levels in tomatoes but applicable to the analysis of lycopene levels in other foods.
Further information For further information on the companies and organisations featured in this article visit the following websites:
www.bachem.com www.biospring.de www.anaspec.com www.jpt.com www.arrayjet.co.uk www.iuct.com www.leitat.org www.oramed.com www.altabiosciences.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48